Transforming growth factor beta receptor type I (TGF-βRI) kinase inhibitors IOA-359 and IOA-360 stimulate...

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Transforming Growth Factor Beta (TGF-β) pathway overactivation contributes to cytopenias in Myelodysplastic syndromes (MDS) and Acute Myeloid Leukemia (AML).
• Targeting the TGF-β pathway is a potential therapeutic strategy for these hematologic malignancies.

Purpose of the Study:

• To evaluate the preclinical efficacy of novel small molecule inhibitors, IOA-359 and IOA-360, targeting the TGF-beta Receptor type I kinase (TGF-βRI/ALK5).
• To assess the potential of these inhibitors in stimulating hematopoietic differentiation, particularly erythroid differentiation, in MDS and AML.

Main Methods:

• Utilized small molecule inhibitors IOA-359 and IOA-360 targeting TGF-βRI/ALK5.
• Assessed inhibition of SMAD phosphorylation and TGF-β mediated gene transcription in hematopoietic cell lines.
• Evaluated the effects of ALK5 inhibitors on TGF-β's growth inhibitory effects on healthy hematopoietic stem cells.
• Tested the capacity of inhibitors to stimulate hematopoietic differentiation in cell lines and patient-derived MDS/AML specimens.

Main Results:

• IOA-359 and IOA-360 effectively abrogated SMAD phosphorylation in hematopoietic cell lines.
• Both inhibitors demonstrated dose-dependent inhibition of TGF-β mediated gene transcription.
• ALK5 inhibitors counteracted TGF-β's growth inhibitory effects on healthy hematopoietic stem cells.
• Inhibitors stimulated hematopoietic differentiation in cell lines and MDS/AML specimens, notably promoting erythroid differentiation.

Conclusions:

• IOA-359 and IOA-360 are potent TGF-βRI/ALK5 inhibitors with demonstrated preclinical efficacy.
• These novel ALK5 inhibitors show promise in stimulating erythroid differentiation in MDS and AML.
• Targeting the TGF-β pathway with IOA-359 and IOA-360 represents a potential therapeutic approach for MDS and AML.